Table 5 Biological relevance of the resultant phenolics

Resveratrol

TNF, SIRT1, IL1B, CASP3, PTGS2, IL6, TP53, RELA, MAPK1, MAPK3

Metabolism–REACT:R-HSA-1430728(4.90e–324), immune system–REACT:R-HSA-168256 (7.89e–284), signal transduction–react:R-HSA-162582 (7.46e–256), innate immune system–REACT:R-HSA-168249 (4.62e–202), metabolic pathways–KEGG:hsa01100 (1.20e–176)

BP: positive regulation of cytosolic calcium ion concentration (2.82e–34), BP: glucose import (9.96e–25), BP: cytosolic calcium ion transport (1.94e–24), BP: internal peptidyl-lysine acetylation (1.00e–17), MF: E-box binding (3.34e–15)

Curcumin

TNF, HMOX1, NFE2L2, BCL2, RELA, CASP3, PTGS2, IL1B, IL6, BAX

Immune system–REACT:R-HSA-168256 (3.15e–178), innate immune system–REACT:R-HSA-168249 (3.11e–143), signal transduction–REACT:R-HSA-162582 (2.18e–142), pathways in cancer-KEGG:hsa05200 (2.08e–141), cytokine signaling in immune system–REACT:R-HSA-1280215 (1.24e–122)

BP: positive regulation of cytosolic calcium ion concentration (1.78e–20), BP: cytosolic calcium ion transport (3.15e–14), BP: glucose import (1.14e–13), BP: activation of protein kinase B activity (1.66e–12), BP: T-helper cell differentiation (8.13e–12)

Quercetin

TNF, CASP3, HMOX1, IL1B, NOS2, MAPK3, NFE2L2, MAPK1, BCL2, AKT1

Immune system–REACT:R-HSA-168256 (6.77e–271), signal transduction–REACT:R-HSA-162582 (1.81e–247), metabolic pathways–KEGG:hsa01100 (9.34e–193), innate immune system–REACT:R-HSA-168249 (1.30e–178), pathways in cancer–KEGG:hsa05200 (1.96e–144)

BP: positive regulation of cytosolic calcium ion concentration (1.63e–23), BP: glucose import (7.99e–22), BP: cytosolic calcium ion transport (4.09e–16), BP: protein polyubiquitination (1.81e–14), BP: internal peptidyl-lysine acetylation (1.80e–12)

Epigallocatechin gallate

ARNTL, AKT1, BDNF, CAT, CREB1, SOD1, BNIP3, CLOCK, COX2, COX4

Tuberculosis–KEGG:hsa05152 (1.03e–21), Hepatitis B–KEGG:hsa05161 (5.22e–21), Non-alcoholic fatty liver disease (NAFLD)–KEGG:hsa04932 (8.26e–21), AGE-RAGE signaling pathway in diabetic complications–KEGG:hsa04933 (6.25e–19), Toxoplasmosis–KEGG:hsa05145 (2.85e–18)

MF: E-box binding (6.31e–9), BP: internal peptidyl-lysine acetylation (1.95e–6), MF: RNA polymerase II proximal promoter sequence-specific DNA binding (4.55e–10), BP: positive regulation of protein serine/threonine kinase activity (4.97e–10), BP: activation of protein kinase activity (6.94e–9)

Genistein

ESR1, ESR2, CFTR, CASP3, TNF, PGR, CYP1A1, MAPK3, MAPK1, PTGS

Immune System–REACT:R-HSA-168256 (2.97e–210), Metabolism–REACT:R-HSA-1430728 (6.69e–207), Signal Transduction–REACT:R-HSA-162582 (9.81e–201), Innate Immune System-REACT:R-HSA-168249 (1.01e–158), Pathways in cancer–KEGG:hsa05200 (3.10e–137)

BP: positive regulation of cytosolic calcium ion concentration (4.38e–31), BP: cytosolic calcium ion transport (3.97e–19), BP: glucose import (2.80e–14), BP: iron ion homeostasis (3.87e–12), BP: T-helper cell differentiation (4.24e–12)